MULTIPLE MYELOMA (MM)

This study tests a new drug, linvoseltamab, combined with standard treatments (bortezomib and lenalidomide) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. Researchers want to see if this new combination works better than the current s…

This early-stage study tests a new treatment called LVIVO-TaVec400 for people with multiple myeloma that has come back or stopped responding to other therapies. The treatment uses specially modified immune cells to attack the cancer. The main goals are to check safety, find the b…

This study tests whether a new drug called HLX15-SC works as well as the approved drug DARZALEX FASPRO® for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. About 258 participants will receive either the new drug or the approved one, along with…

This study tests whether two bispecific antibodies (teclistamab and talquetamab) given in sequence can improve survival in 50 people with high-risk multiple myeloma. Participants will receive chemotherapy, immunotherapy, and possibly a stem cell transplant depending on how well t…

This study tests a new drug called BT02 in people with blood cancers (leukemia, lymphoma, or multiple myeloma) that have returned or not improved with standard treatments. About 116 adults aged 18 to 70 will receive the drug by IV every 2-3 weeks for up to 2 years. The main goals…

This early-stage study tests a new drug called QI-019B in 24 adults with multiple myeloma that has returned or not responded to at least two prior treatments. The main goal is to check safety and side effects, while also seeing if the drug can shrink the cancer. It is a single-ce…

This early-stage trial tests a new drug called BR101 injection in 10 adults with multiple myeloma that has returned or not responded to prior treatments. The main goals are to find the safest dose and check for side effects. Researchers will also look at whether the drug helps sh…

This study compares a new drug called CM336 to the usual treatments for people with multiple myeloma that has come back or stopped responding after at least two prior therapies. About 280 adults will be randomly assigned to receive either CM336 or a standard treatment chosen by t…

This early-stage study tests an experimental drug called QI-019A in 24 adults with multiple myeloma that has returned or stopped responding to at least two prior treatments. The main goal is to check the drug's safety and find the right dose, while also looking at how well it wor…

This study tests a new type of PET scan that uses a special tracer (68Ga-BCMA nanobody) to find multiple myeloma lesions in the body. Researchers will compare it to the standard FDG-PET scan to see if it detects more disease spots. The goal is to improve diagnosis, staging, and e…

This study looks at whether a 12-week resistance exercise program can improve quality of life, reduce frailty, and boost mental health in people with multiple myeloma. About 50 patients will be split into two groups: one doing supervised exercise and the other exercising at home.…

This study tests a 16-week lifestyle program that encourages healthier eating and exercise habits in people with multiple myeloma. Researchers want to see if these changes improve physical function, quality of life, and blood markers of aging. About 184 adults who have had myelom…

This study looks at whether adding special breathing exercises to a standard exercise program can improve heart and lung function in people with multiple myeloma. About 26 adults currently on a specific treatment will take part. They will be split into two groups, both doing exer…